Citations

Clear

4847 citation(s) found for "Yu, Eric".

White matter hyperintensities in former American football players
Alosco, Michael L. , Baucom, Zachary, Balcer, Laura J. , Bernick, Charles , Mariani, Megan, Banks, Sarah J. , Wethe, Jennifer V. , Coleman, Michael J. , McKee, Ann C. , Palmisano, Joseph , Martin, Brett , Hartlage, Kaitlin , Lin, Alexander , Reiman, Eric M. , Shenton, Martha E. , Wethe, Jennifer V , Shenton, Martha E , Tripodis, Yorghos , Adler, Charles H. , Au, Rhoda , Barr, William , Cantu, Robert C. , Dodick, David W. , McClean, Michael D , Mez, Jesse , Koerte, Inga K , Cummings, Jeffrey L. , Stern, Robert A. , Bouix, Sylvain

Mayo Clinic

Alzheimer's & Dementia | August 23, 2022 | Volume: 19 | Issue: 4 | Pages: 1260-1273

10.1002/alz.12779 | PMID 35996231 Get It

AbstractIntroductionThe presentation, risk factors, and etiologies of white matter hyperintensities (WMH) in people exposed to repetitive head impacts are unknown. We examined the burden and distribution of WMH, and their association with years of play, age of first exposure, and clinical function in former American football players.MethodsA total of 149 former football players and 53 asymptomatic unexposed participants (all men, 45–74 years) completed fluid‐attenuated inversion recovery magnetic resonance imaging, neuropsychological testing, and self‐report neuropsychiatric measures. Lesion Segmentation Toolbox estimated WMH. Analyses were performed in the total sample and stratified by age 60.ResultsIn older but not younger participants, former football players had greater total, frontal, temporal, and parietal log‐WMH compared to asymptomatic unexposed men. In older but not younger former football players, greater log‐WMH was associated with younger age of first exposure to football and worse executive function.DiscussionIn older former football players, WMH may have unique presentations, risk factors, and etiologies.Highlights Older but not younger former football players had greater total, frontal, temporal, and parietal lobe white matter hyperintensities (WMH) compared to same‐age asymptomatic unexposed men. Younger age of first exposure to football was associated with greater WMH in older but not younger former American football players. In former football players, greater WMH was associated with worse executive function and verbal memory.
A comprehensive review of Strongyloides stercoralis infection after solid organ and hematopoietic stem cell transplantation
Abad, Cybéle Lara R. , Bhaimia, Eric , Schuetz, Audrey N. , Razonable, Raymund R. , Razonable, Raymund R , Schuetz, Audrey N

Mayo Clinic

Clinical Transplantation | August 20, 2022 | Volume: 36 | Issue: 11 | Pages: No page available

10.1111/ctr.14795 | PMID 35987856 Get It

Abstract Background We reviewed the scientific literature to gain insight on the epidemiology and outcome of Strongyloides stercoralis infections after transplantation. Methods CINAHL, PUBMED, and OVID/MEDLINE were reviewed from inception through March 31, 2022 using key words Strongyloides and transplantation. Results Our review identified 108 episodes of Strongyloides infection among 91 solid organ transplant (SOT) and 15 hematopoietic cell transplant (HCT) recipients. Median time to infection was 10.8 (range, .14–417) and 8.8 (range, 0–208) weeks after SOT and HCT, respectively. Gastrointestinal symptoms were frequent (86/108 [79.6%]), while skin rash (22/108 [20.3%]) and fever (31/103 [30%]) were less common. Peripheral eosinophilia was observed in half of patients (41/77 [53.2%]). Bacteremia (31/59 [52.5%]) was frequently due to Gram‐negative organisms (24/31 [77.4%]). Abnormal chest radiologic findings were reported in half (56/108 [51.9%]). The majority had hyperinfection syndrome (97/108 [89.8%]) while disseminated strongyloidiasis was less common (11/108 [10.2%]). Thirty‐two cases were categorized as donor‐derived infection (DDI), with donors (23/24 [95.8%]) who had traveled to or lived in endemic areas. Median time to DDI was 8 weeks (range .5–34.3 weeks) after transplantation. Treatment consisted of ivermectin ( n = 26), a benzimidazole ( n = 27), or both drugs ( n = 28). There was high all‐cause mortality (48/107, 44.9%) and a high Strongyloides ‐attributable mortality (32/49, 65.3%). Conclusions Strongyloidiasis should be strongly considered among recipients with epidemiologic risk factors for infection, even in the absence of eosinophilia or rash. A policy that provides guidance on pro‐active screening is needed, to ensure preventive measures are provided to recipients at increased risk.
A fast GPU‐accelerated Monte Carlo engine for calculation of MLC‐collimated electron fields
Brost, Eric E., Tseung, H. Wan Chan, Antolak, John A. , Brost, Eric

Mayo Clinic

Medical Physics | August 20, 2022 | Volume: 50 | Issue: 1 | Pages: 600-618

10.1002/mp.15938 | PMID 35986907 Get It

AbstractBackgroundAlthough intensity‐modulated radiation therapy and volumetric arc therapy have revolutionized photon external beam therapies, the technological advances associated with electron beam therapy have fallen behind. Modern linear accelerators contain technologies that would allow for more advanced forms of electron treatments, such as beam collimation, using the conventional photon multi‐leaf collimator (MLC); however, no commercial solutions exist that calculate dose from such beam delivery modes. Additionally, for clinical adoption to occur, dose calculation times would need to be on par with that of modern dose calculation algorithms.PurposeThis work developed a graphics processing unit (GPU)‐accelerated Monte Carlo (MC) engine incorporating the Varian TrueBeam linac head geometry for a rapid calculation of electron beams collimated using the conventional photon MLC.MethodsA compute unified device architecture framework was created for the following: (1) transport of electrons and photons through the linac head geometry, considering multiple scattering, Bremsstrahlung, Møller, Compton, and pair production interactions; (2) electron and photon propagation through the CT geometry, considering all interactions plus the photoelectric effect; and (3) secondary particle cascades through the linac head and within the CT geometry. The linac head collimating geometry was modeled according to the specifications provided by the vendor, who also provided phase‐space files. The MC was benchmarked against EGSnrc/DOSXYZnrc/GEANT by simulating individual interactions with simple geometries, pencil, and square beam dose calculations in various phantoms. MC‐calculated dose distributions for MLC and jaw‐collimated electron fields were compared to measurements in a water phantom and with radiochromic film.ResultsPencil and square beam dose distributions are in good agreement with DOSXYZnrc. Angular and spatial distributions for multiple scattering and secondary particle production in thin slab geometries are in good agreement with EGSnrc and GEANT. Dose profiles for MLC and jaw‐collimated 6–20‐MeV electron beams showed an average absolute difference of 1.1 and 1.9 mm for the FWHM and 80%–20% penumbra from measured profiles. Percent depth doses showed differences of <5% for as compared to measurement. The computation time on an NVIDIA Tesla V100 card was 2.5 min to achieve a dose uncertainty of <1%, which is ∼300 times faster than published results in a similar geometry using a single‐CPU core.ConclusionsThe GPU‐based MC can quickly calculate dose for electron fields collimated using the conventional photon MLC. The fast calculation times will allow for a rapid calculation of electron fields for mixed photon and electron particle therapy.
Effectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application
Pletcher, Mark J. , Modrow, Madelaine Faulkner , Todd, Jonathan , O’Brien, Emily C. , Sheer, Amy , Park, Soo , Orozco, Jaime , Maeztu, Carlos , Pletcher, Mark J , Faulkner Modrow, Madelaine , Fontil, Valy , Carton, Thomas W. , Chamberlain, Alanna M. , Vittinghoff, Eric , Lin, Feng , Wozniak, Gregory , Rakotz, Michael , Shay, Christina M. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

JAMA Internal Medicine | August 19, 2022 | Volume: 182 | Issue: 10 | Pages: 1025

10.1001/jamainternmed.2022.3355 | PMID 35969408 Get It

ImportanceSelf-measured blood pressure (SMBP) with commercially available connected smartphone applications may help patients effectively use SMBP measurements.ObjectiveTo determine if enhanced SMBP paired with a connected smartphone application was superior to standard SMBP for blood pressure (BP) reduction or patient satisfaction.Design, Setting, and ParticipantsThis randomized clinical trial was conducted among 23 health systems participating in PCORnet, the National Patient-Centered Clinical Research Network, and included patients who reported having uncontrolled BP at their last clinic visit, a desire to lower their BP, and a smartphone. Enrollment and randomization occurred from August 3, 2019, to December 31, 2020, which was followed by 6 months of follow-up for each patient. Analysis commenced shortly thereafter.InterventionsEligible participants were randomly assigned to enhanced SMBP using a device that paired with a connected smartphone application (enhanced) or a standard device (standard). Participants received their device in the mail, along with web-based educational materials and phone-based support as needed. No clinician engagement was undertaken, and the study provided no special mechanisms for delivering measurements to clinicians for use in BP management.Main Outcomes and MeasuresReduction in systolic BP, defined as the difference between clinic BP at baseline and the most recent clinic BP extracted from electronic health records at 6 months.ResultsEnrolled participants (1051 enhanced [50.0%] vs 1050 standard [50.0%]; 1191 women [56.7%]) were mostly middle-aged or older (mean [SD] age, 58 [13] years), nearly a third were Black or Hispanic (645 [31%]), and most were relatively comfortable using technology (mean [SD], 4.1 [1.1] of 5). The mean (SD) change in systolic BP from baseline to 6 months was −10.8 (18) mm Hg vs −10.6 (18) mm Hg (enhanced vs standard: adjusted difference, −0.19 mm Hg; 95% CI, −1.83 to 1.44;P = .81). Secondary outcomes were mostly null, except for documented attainment of BP control to lower than 140/&amp;lt;90 mm Hg, which occurred in 32% enhanced vs 29% standard groups (odds ratio, 1.15; 95% CI, 1.01-1.34). Most participants were very likely to recommend their SMBP device to a friend (70% vs 69%).Conclusions and RelevanceThis randomized clinical trial found that enhanced SMBP paired with a smartphone application is not superior to standard SMBP for BP reduction or patient satisfaction.Trial RegistrationClinicalTrials.gov Identifier:NCT03796689
Developing a Social Media Ontology Across Otolaryngology and its Subspecialties
Flagg, Candace A. , Marinelli, John P. , Carlson, Matthew L. , Kezirian, Eric J. , Dion, Gregory R. , Abel, Kathryn M. Van , Bowe, Sarah N. , Van Abel, Kathryn M , Choby, Garret , Bowe, Sarah N , Kezirian, Eric J , Dion, Greg , Choby, Garret , Hamilton, Grant

Mayo Clinic

The Laryngoscope | August 17, 2022 | Volume: 133 | Issue: 7 | Pages: 1595-1599

10.1002/lary.30345 | PMID 37294045 Get It

ObjectiveTo determine how social media is used in the dissemination of new information within otolaryngology, and to emphasize the importance of standardizing Twitter hashtag use.MethodsBased on the 2019 SCImago journal rankings, the Twitter posts from the accounts of the top three journals covering each otolaryngology subspecialty were reviewed from August 1, 2020 to May 1, 2021. Twitter posts from the primary otolaryngology‐related academic societies were also reviewed during this timeframe. A list of hashtags was generated based on a combination of the most common otolaryngologic procedures and most commonly used hashtags in the social media space. This list was then crowd‐sourced with 10 fellowship‐trained otolaryngologists for each subspecialty.ResultsHashtag use among key stakeholders in the otolaryngology social media space varies considerably. For instance, #HNSCC, #HeadAndNeckSquamousCellCarcinoma, #HeadAndNeckCancer, #HeadAndNeckCancers, #OropharyngealCancer, #OropharynxCancer, #OralCancer, and #OPSCC were all commonly used hashtags to identify posts discussing oropharyngeal squamous cell carcinoma. #HeadAndNeckCancer and #HNSCC were most popular and used in a total of 85 and 65 tweets, respectively. #HeadAndNeckCancer was found alone in 32 out of 85 tweets (38%), whereas #HNSCC was found alone in 27 out of 65 tweets (42%). A standardized hashtag ontology covering all subspecialties within otolaryngology is proposed herein.ConclusionsAdoption of a standardized social media ontology within otolaryngology will improve information dissemination across all key stakeholders. Laryngoscope, 133:1595–1599, 2023
Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Labadie, Jessica G. , Worley, Brandon , Kang, Bianca Y. , Rakita, Uros , Rigali, Sarah , Arndt, Kenneth A., Brauer, Jeremy A., Chandra, Sunandana , Didwania, Aashish , DiGiorgio, Catherine M., Donelan, Mattias, Dover, Jeffrey S. , Geronemus, Roy G. , Goldman, Mitchel P. , Hruza, George J. , Ibrahimi, Omar A. , Kauvar, Arielle N.B. , Kelly, Kristen M. , Krakowski, Andrew C. , Miest, Rachel Y. , Orringer, Jeffrey S. , Ozog, David , Ross, E. Victor , Shumaker, Peter R. , Sobanko, Joseph F. , Suozzi, Kathleen C. , Taylor, Mark B., Teng, Joyce , Uebelhoer, Nathan S., Waibel, Jill , Wanner, Molly, Ratchev, Ina, Poon, Emily , Miller, Corinne H. , Alam, Murad , Miest, Rachel, Kelly, Kristen M , Ibrahim, Sarah A. , Bernstein, Eric F. , Galadari, Hassan , Hædersdal, Merete , Christensen, Rachel E. , Alam, Murad

Mayo Clinic

JAMA Dermatology | August 17, 2022 | Volume: 158 | Issue: 10 | Pages: 1193

10.1001/jamadermatol.2022.3234 | PMID 35976634 Get It

Importance Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD. Objective To develop recommendations for the safe and effective use of LADD. Evidence Review A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved. Findings Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections. Conclusions and Relevance This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
Spontaneous Regression of Metastatic Lung Adenocarcinoma Following a Core Biopsy
Samhouri, Bilal F. , Edell, Eric S. , Dimou, Anastasios , Boland, Jennifer M.

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | August 12, 2022 | Volume: 30 | Issue: 2 | Pages: 181-184

10.1097/lbr.0000000000000867 | PMID 35959896 Get It

Transoral Robotic Surgery for Recurrent Tumors of the Upper Aerodigestive Tract (RECUT): An International Cohort Study
Hardman, John , Holsinger, F. Christopher , Brady, Grainne , Beharry, Avinash , Bonifer, Alec , D’Andréa, Grégoire , Dabas, Surender, Almeida, John R. de , Duvvuri, Umamaheswar , Floros, Peter , Ghanem, Tamer , Hamilton, David W. , Larsen, Mikkel Hjordt Holm , Magnuson, J. Scott , Miles, Brett A., Moore, Eric J. , Pantvaidya, Gouri , Rubek, Niclas , Simon, Christian , Abel, Kathryn M. Van , Poorten, Vincent Vander , Walgama, Evan , Greenlay, Emily, Potts, Laura, Balaji, Arun, Starmer, Heather M. , Stephen, S. , Roe, Justin , Harrington, Kevin J. , Paleri, Vinidh , Hardman, John C , Holsinger, F Chris , Brady, Grainne C , Bonifer, Alec T , de Almeida, John R , Ghanem, Tamer A , Gorphe, Philippe , Gross, Neil D , Hamilton, David , Kurukulasuriya, Chareeni , Larsen, Mikkel Hjordt Holm , Lin, Daniel J , Magnuson, J Scott , Meulemans, Jeroen , Miles, Brett A , Moore, Eric J , Pantvaidya, Gouri , Roof, Scott , Rubek, Niclas , Subash, Anand , Topf, Michael C , Van Abel, Kathryn M , Vander Poorten, Vincent , Walgama, Evan S , Greenlay, Emily , Potts, Laura , Balaji, Arun , Roe, Justin , Harrington, Kevin , Paleri, Vinidh , Topf, Michael C.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 9, 2022 | Volume: 114 | Issue: 10 | Pages: 1400-1409

10.1093/jnci/djac130 | PMID 35944904 Get It

Abstract Background Transoral robotic surgery (TORS) is an emerging minimally invasive surgical treatment for residual, recurrent, and new primary head and neck cancers in previously irradiated fields, with limited evidence for its oncological effectiveness. Methods A retrospective observational cohort study of consecutive cases performed in 16 high-volume international centers before August 2018 was conducted (registered at clinicaltrials.gov [NCT04673929] as the RECUT study). Overall survival (OS), disease-free survival, disease-specific survivals (DSS), and local control (LC) were calculated using Kaplan-Meier estimates, with subgroups compared using log-rank tests and Cox proportional hazards modeling for multivariable analysis. Maximally selected rank statistics determined the cut point for closest surgical resection margin based on LC. Results Data for 278 eligible patients were analyzed, with median follow-up of 38.5 months. Two-year and 5-year outcomes were 69.0% and 62.2% for LC, 71.8% and 49.8% for OS, 47.2% and 35.7% for disease-free survival, and 78.7% and 59.1% for disease-specific survivals. The most discriminating margin cut point was 1.0 mm; the 2-year LC was 80.9% above and 54.2% below or equal to 1.0 mm. Increasing age, current smoking, primary tumor classification, and narrow surgical margins (≤1.0 mm) were statistically significantly associated with lower OS. Hemorrhage with return to theater was seen in 8.1% (n = 22 of 272), and 30-day mortality was 1.8% (n = 5 of 272). At 1 year, 10.8% (n = 21 of 195) used tracheostomies, 33.8% (n = 66 of 195) used gastrostomies, and 66.3% (n = 53 of 80) had maintained or improved normalcy of diet scores. Conclusions Data from international centers show TORS to treat head and neck cancers in previously irradiated fields yields favorable outcomes for LC and survival. Where feasible, TORS should be considered the preferred surgical treatment in the salvage setting.
Dismissal disagreement and discharge delays: Associations of patient–clinician plan of care agreement with discharge outcomes
Olson, Emily M. , Falde, Samuel D., Wegehaupt, Abigail K., Halvorsen, Andrew J. , Lawson, Donna K. , Ratelle, John T. , Ratelle, John T , Polley, Eric C.

Mayo Clinic

Journal of Hospital Medicine | August 9, 2022 | Volume: 17 | Issue: 9 | Pages: 710-718

10.1002/jhm.12929 | PMID 35942985 Get It

AbstractBackgroundMany hospitalized patients do not understand or agree with their clinicians about their discharge plan. However, the effect of disagreement on discharge outcomes is unknown.ObjectiveTo measure the correlation between patient‐clinician care agreement and discharge outcomes.DesignA prospective cohort study was performed from September 2019 to March 2020 (Rochester, MN, USA).Setting and ParticipantsInternal medicine patients and their primary clinician (resident, advanced practice clinician or attending) hospitalized from September 2019‐March 2020 at Mayo Clinic Hospital. Participants were independently surveyed following hospital day #3 ward rounds regarding the goals of the hospitalization and discharge planning.Main Outcome and MeasuresPatient–clinician agreement for main diagnosis, patient's main concern, and four domains of discharge planning was assessed. Readiness for hospital discharge, delayed discharge, and 30‐day readmission was measured. Then, associations between patient‐clinician agreement, delayed discharge, and 30‐day readmissions were analyzed using multivariable logistic regression.ResultsOf the 436 patients and clinicians, 17.7% completely agreed about what needs to be accomplished before dismissal, 40.8% agreed regarding discharge date, and 71.1% agreed regarding discharge location. In the multivariable model, patient–clinician agreement scores were not significantly correlated with discharge outcomes. Patient–clinician agreement on discharge location was higher for those discharged to home (81.5%) versus skilled nursing facility (48.5%) or assisted living (42.9%) (p < .0001). The agreement on the expected length of stay was highest for home‐goers (45.9%) compared to skilled nursing (32.0%) or assisted living (21.4%) (p = .004).ConclusionsPatients and their clinicians frequently disagree about when and where a patient will go after hospitalization, particularly for those discharged to a skilled nursing facility. While disagreement did not predict discharge outcomes, our findings suggest opportunities to improve effective communication and promote shared mental models regarding discharge earlier in the hospital stay.
Risk of Sudden Death in a General Unbiased Epidemiological Cohort of Sarcoidosis
Chahal, C. Anwar A. , Brady, Peter A. , Lin, Grace , Somers, Virend K. , Crowson, Cynthia S. , Matteson, Eric L. , Ungprasert, Patompong , Cooper, Leslie T , Lin, Grace , Somers, Virend K. , Chahal, Choudhary Anwar A , Cooper, Leslie T.

Mayo Clinic

Journal of the American Heart Association | August 5, 2022 | Volume: 11 | Issue: 16 | Pages: No page available

10.1161/jaha.122.025479 | PMID 35929471 Get It

Background Sarcoidosis is an inflammatory, noncaseating, granulomatous disorder of unknown cause that can affect any body system and is associated with cardiovascular disease including sudden cardiac death (SCD). Cardiac involvement in sarcoidosis is associated with higher risk of SCD, but the SCD risk in the general sarcoidosis population is unknown. We aimed to determine the risk of SCD in people with sarcoidosis versus the matched general population. Methods and Results A population‐based cohort of sarcoidosis and age‐ and sex‐matched comparators from January 1, 1976 to December 31, 2013 was used; presence of other comorbidities in the comparator group was not an exclusion criterion. Mortality, including time, place, and cause of death were measured and manually adjudicated for SCD events. Incidence rates are reported per 100 000 person‐years, and Cox models were used for group comparisons. Of the 345 incident cases of sarcoidosis (171 men; 50%) there were 58 reported deaths; 10 were definite/probable SCD versus 57 all‐cause and 9 SCDs in comparators. Median follow‐up was 12.9 years (interquartile range, 6.0–23.4 years) . Incidence rate of SCD in sarcoidosis was 192 (95% CI, 92–352) versus 155 (95% CI, 71–294) in comparators (hazard ratio [HR], 1.28 (95% CI, 0.52–3.17). Nocturnal deaths were more frequent in sarcoidosis 57 (95% CI, 12–168) versus 17 (95% CI, 0.4–95) (HR, 3.76 [95% CI, 0.39–36.47]). No significant differences were detected between the groups by sex, age, calendar year of diagnosis, or disease duration. Conclusions In a population‐based cohort of patients with sarcoidosis, the risk for SCD compared with matched comparators was not increased. There were more nocturnal deaths among patients with sarcoidosis, yet this was statistically insignificant.